Investigators presented numerous studies into new and developing therapies for diabetic macular edema and age-related macular degeneration that were aimed at reducing the treatment burden.

The nearer-looming threat of a biosimilar from Amgen Inc. to heavyweight Regeneron Pharmaceuticals Inc.’s age-related macular ...

Add a description, image, and links to the molecule-driver topic page so that developers can more easily learn about it.

The molecule, called pyrene, is made up of four fused planar rings of carbon. It's therefore categorized as a polycyclic aromatic hydrocarbon (PAH) — one of the most abundant complex molecules ...

One key study focused on the effectiveness of 8 mg aflibercept, showing that while all patients benefited, those with previously treated DME might require more frequent dosing compared with ...

Indian drugmaker Biocon (BSE: 532523) subsidiary Biocon Biologicals has released a new extension study evaluating MYL-1701P, a proposed biosimilar to ophthalmic drug aflibercept, which is marketed by ...

A crucial molecule for brain health acts as a garbage collector of other fat molecules (lipids), despite also being a lipid itself. So for more than half a century, researchers have puzzled over how ...

On 21 October 2024, at the 128th Annual Meeting of the American Academy of Ophthalmology (AAO) 2024 in Chicago, US, a matching-adjusted meta-analysis that indirectly compared the efficacies of Eylea ...

Oct 22 (Reuters) - Amgen (AMGN.O), opens new tab will launch its biosimilar version of Regeneron's (REGN.O), opens new tab blockbuster eye care drug Eylea following a U.S. appeals court ruling in ...

The study comprised 161 patients split between three arms: EYP-1901 2mg (low dose; n=53); EYP-1901 3mg (high dose, n=54); and the standard of care, which was aflibercept 2mg every eight weeks (n=54).

I just felt I could do so much more. And I really do credit NAD for it.” Camilla Thompson credits the NAD molecule for her improved functioning.Credit: Syl Marie NAD – Nicotinamide adenine ...